TABLE 1.

Comparison of the intranasal and oral routes for the generation of D2-specific serum antibody to CPMV-MAST1^a

Route	Mean endpoint titer ± SD with:
	No adjuvant	ISCOM matrix	CT
Nasal	81,920 ± 28,043bc	37,120 ± 20,439b	NT
Oral	9,200 ± 10,460	6,320 ± 10,831	7,800 ± 10,407

^aMice were immunized intranasally or orally with 100 μg of CPMV-MAST1 either without or with the ISCOM matrix and CT (oral route only) on days 0, 7, 14, and 21. On day 42 (oral) and day 49 (nasal) sera were collected and tested for GSTD1-3 IgG1 and IgG2a (a mixture of the two conjugates) by ELISA. Titers are expressed as the mean endpoint titers ± the SD obtained with sera from the mice in each group. NT, not tested. 

^bComparison between nasal and oral administrations for each group. P < 0.001. 

^cComparison between nasal administration, with or without adjuvant. P < 0.05.